| abstract |
Compositions for treating or controlling degeneration of at least a component of the human optic nerve system comprise a modulator of protein kinase Gdelta ('PKC-delta'). Such a PKC-delta modulator can be a compound that substantially inhibits, reduces, or interferes with, an activity of a cell signaling cascade involving PKC-delta or activation of PKC-delta. The compositions can also include an anti-inflammatory medicament. Such compositions can be administered to provide neuroprotection to a patient suffering from an ocular disease, such as glaucoma, AMD, DR, or retinitis pigmentosa. |